University of Sheffield and Pfizer led new €25.5 million project to accelerate development of Advanced Therapy Medicinal Products

25th November 2020

The University of Sheffield and Pfizer have today launched a new consortium which aims to standardize and accelerate the development of Advanced Therapy Medicinal Products (ATMPs), allowing potentially transformative treatments to reach patients sooner.

The new, five-year consortium, Accelerating Research and Innovation for Advanced Therapies (ARDAT), is supported by the Innovative Medicines Initiative (IMI) and brings together the leading expertise of 34 academic, nonprofit and private organisations from across Europe and the US.

Led by ARDAT Coordinator, Professor Mimoun Azzouz from the University of Sheffield, and ARDAT Project Lead, Dr Gregory LaRosa from Pfizer, the new consortium will pioneer a €25.5 million project to accelerate the development of ATMPs which includes gene and cell therapies.

The field of ATMP research is expected to grow exponentially in the coming years, with potentially up to 10-20 new drug applications submitted per year to the FDA (US Food and Drug Administration) by 2025.

The ARDAT consortium will aim to bring together researchers from public and private organisations to help fill the knowledge gaps in how these therapies could potentially work, and to develop appropriate standards to aid researchers, developers and regulators in accelerating effective and safe gene and cell therapies to benefit patients.

Professor Mimoun Azzouz, Chair of Translational Neuroscience and Director of Research and Innovation at the University of Sheffield’s Institute for Translational Neuroscience (SITraN) and ARDAT Coordinator, said: “This is a significant development expected to change the landscape of research, innovation and regulatory activities for cell and gene therapies.

“We are very excited to bring together world-leading experts to accelerate delivery of advanced therapies to patients suffering from rare diseases.”

The consortium aims to develop standardized models for predicting ATMP immunogenicity in humans; build understanding of ATMP drug metabolism within a host; identify adaptive immune responses that could affect ATMP safety, efficacy and persistence; and engage regulators to help support filings that address standardized regulatory, safety and efficacy concerns.

“While still an emerging field, ATMP research has largely been fragmented and siloed within organisations with little opportunity to share best practices and information,” said Dr Greg LaRosa, Head of Scientific Research, Rare Disease Research Unit at Pfizer.

“As gene and cell therapies research grows and more potential ATMPs move into later-stage clinical trials, it is in the interest of the industry and of patients to further our collective understanding of their mechanisms by sharing data and regulatory expertise.”

You might also be interested in

Brexit transition period ended: What this means for employers in the UK manufacturing industry

Fri 18th June 2021

Laxmi Limbani of Fragomen discusses the impact of the end of free movement on the manufacturing industry in the UK in advance of the upcoming EUSS deadline

Shadow Minister meets next generation of Hallam degree apprentices

Thu 17th June 2021

Toby Perkins heard about how Sheffield Hallam was one of the first providers of degree apprenticeships and how the University now delivers one of the widest selection of courses in the UK, with more than 1500 apprentices across 400 employers.

Hentons plan for the future with two new tax experts

Thu 17th June 2021

Sheffield based chartered accountancy and business advisory firm Hentons has made two new appointments, within its specialist Tax Advisory team.

Government ‘super-deduction’ tax incentive supports net zero targets

Thu 17th June 2021

Energy Partner Professional Energy Purchasing provides a member update on the 130 tax break for new plant and machinery announced in the March 2021 budget.